BioSyent Future Growth
Future criteria checks 1/6
BioSyent is forecast to grow revenue at 9.9% per annum. EPS is expected to grow by 7% per annum.
Key information
n/a
Earnings growth rate
7.0%
EPS growth rate
| Pharmaceuticals earnings growth | 56.8% |
| Revenue growth rate | 9.9% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 15 Mar 2024 |
Recent future growth updates
Recent updates
BioSyent's (CVE:RX) Profits May Not Reveal Underlying Issues
Mar 22
BioSyent (CVE:RX) Will Pay A Larger Dividend Than Last Year At CA$0.045
Feb 09BioSyent Inc.'s (CVE:RX) Intrinsic Value Is Potentially 38% Above Its Share Price
Apr 14BioSyent Inc. (CVE:RX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Mar 19Declining Stock and Solid Fundamentals: Is The Market Wrong About BioSyent Inc. (CVE:RX)?
Mar 17BioSyent (CVE:RX) Shareholders Booked A 33% Gain In The Last Year
Feb 18
Here's Why BioSyent's (CVE:RX) Statutory Earnings Are Arguably Too Conservative
Jan 28BioSyent Inc. (CVE:RX) Shares Could Be 30% Below Their Intrinsic Value Estimate
Jan 07BioSyent Inc.'s (CVE:RX) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Dec 17Did BioSyent Inc. (CVE:RX) Insiders Buy Up More Shares?
Dec 02Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 43 | N/A | N/A | N/A | 1 |
| 12/31/2025 | 39 | N/A | N/A | N/A | 1 |
| 12/31/2024 | 35 | N/A | N/A | N/A | 1 |
| 12/31/2023 | 32 | 6 | 5 | 5 | N/A |
| 9/30/2023 | 31 | 6 | 6 | 7 | N/A |
| 6/30/2023 | 29 | 5 | 5 | 5 | N/A |
| 3/31/2023 | 27 | 5 | 3 | 4 | N/A |
| 12/31/2022 | 28 | 5 | 4 | 5 | N/A |
| 9/30/2022 | 28 | 6 | 4 | 5 | N/A |
| 6/30/2022 | 28 | 6 | 6 | 6 | N/A |
| 3/31/2022 | 28 | 6 | 5 | 5 | N/A |
| 12/31/2021 | 29 | 6 | 5 | 5 | N/A |
| 9/30/2021 | 27 | 5 | 5 | 5 | N/A |
| 6/30/2021 | 26 | 4 | 4 | 4 | N/A |
| 3/31/2021 | 24 | 4 | 5 | 6 | N/A |
| 12/31/2020 | 22 | 4 | 7 | 7 | N/A |
| 9/30/2020 | 22 | 4 | 10 | 8 | N/A |
| 6/30/2020 | 23 | 5 | 6 | 7 | N/A |
| 3/31/2020 | 23 | 5 | 4 | 5 | N/A |
| 12/31/2019 | 21 | 4 | 4 | 4 | N/A |
| 9/30/2019 | 22 | 5 | 1 | 4 | N/A |
| 6/30/2019 | 21 | 5 | 4 | 5 | N/A |
| 3/31/2019 | 22 | 6 | 5 | 6 | N/A |
| 12/31/2018 | 22 | 6 | 6 | 6 | N/A |
| 9/30/2018 | 22 | 5 | 6 | 7 | N/A |
| 6/30/2018 | 22 | 6 | 6 | 7 | N/A |
| 3/31/2018 | 21 | 5 | 6 | 7 | N/A |
| 12/31/2017 | 21 | 5 | 6 | 7 | N/A |
| 9/30/2017 | 20 | 5 | N/A | 6 | N/A |
| 6/30/2017 | 19 | 5 | N/A | 5 | N/A |
| 3/31/2017 | 18 | 4 | N/A | 5 | N/A |
| 12/31/2016 | 18 | 4 | N/A | 4 | N/A |
| 9/30/2016 | 17 | 4 | N/A | 3 | N/A |
| 6/30/2016 | 17 | 4 | N/A | 4 | N/A |
| 3/31/2016 | 16 | 4 | N/A | 4 | N/A |
| 12/31/2015 | 15 | 4 | N/A | 3 | N/A |
| 9/30/2015 | 15 | 4 | N/A | 3 | N/A |
| 6/30/2015 | 14 | 4 | N/A | 3 | N/A |
| 3/31/2015 | 13 | 4 | N/A | 3 | N/A |
| 12/31/2014 | 12 | 3 | N/A | 4 | N/A |
| 9/30/2014 | 11 | 3 | N/A | 3 | N/A |
| 6/30/2014 | 10 | 3 | N/A | 2 | N/A |
| 3/31/2014 | 9 | 2 | N/A | 2 | N/A |
| 12/31/2013 | 8 | 2 | N/A | 2 | N/A |
| 9/30/2013 | 7 | 2 | N/A | 1 | N/A |
| 6/30/2013 | 6 | 2 | N/A | 1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if RX's forecast earnings growth is above the savings rate (2%).
Earnings vs Market: Insufficient data to determine if RX's earnings are forecast to grow faster than the Canadian market
High Growth Earnings: Insufficient data to determine if RX's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: RX's revenue (9.9% per year) is forecast to grow faster than the Canadian market (6.6% per year).
High Growth Revenue: RX's revenue (9.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RX's Return on Equity is forecast to be high in 3 years time